When you have cancer act as if there is no tomorrow, believe you will live forever; focus on your life not on the disease

Daniel Weber M.Sc. Ph.D.


Daniel Weber began his study of Oriental Medicine in 1969 in Boston. He studied with J. R. Worsley and J. D. van Buren in the UK from 1974 before receiving his B.Ac. Daniel went to Japan in 1976 and studied with Dr. Masahiro Oki and Dr. Okada. He has been in practice in Sydney Australia since 1977 and created the first English language data base for Chinese herbal medicine in 1992. This data base was awarded 'Innovations in Australian Design' and put on exhibit in the Powerhouse Museum.

Daniel has studied in China from 1988, visiting more than a dozen times with numerous awards and two honorary Ph.Ds as well as being an advisor to Hangzhou TCM Institute in Hangzhou. Daniel has a Master of Health Science (Aust) and is completing his research Doctorate. Daniel is not just an academic but a committed clinician, and continues a clinic as well as his ongoing studies. His research into complimentary cancer treatments and his seminars to practitioners in Australia, South Africa and the US have attracted positive comment from leaders in the field. He is committed to creating a dialogue between all types of health care professionals.

Resveratrol - Leukaemia


Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia.


Roman V , Billard C , Kern C , Ferry-Dumazet H , Izard JC , Mohammad R , Mossalayi DM , Kolb JP .


U.365 INSERM, Institut Curie, 26 rue d'Ulm, 75248 Paris cedex 05, France .


Trans-resveratrol was analysed for its apoptotic and growth inhibitory activity in human B-cell lines derived from chronic B-cell malignancies (WSU-CLL and ESKOL), and in leukaemic lymphocytes from patients with B-cell chronic lymphocytic leukaemia (B-CLL). Resveratrol displayed antiproliferative activity on both B-cell lines, as estimated by the decrease in cell recovery and inhibition of thymidine uptake. Furthermore, resveratrol induced apoptosis in the two cell lines as well as in B-CLL patients' cells, as evidenced by the increase in annexin V binding, caspase activation, DNA fragmentation and decrease of the mitochondrial transmembrane potential DeltaPsim. We previously reported that nitric oxide (NO), endogenously released by an iNO synthase (iNOS) spontaneously expressed in these leukaemic cells, contributed to their resistance towards apoptosis. We show here that resveratrol inhibited both iNOS protein expression and in situ NO release in WSU-CLL, ESKOL and B-CLL patients'cells. In addition, Bcl-2 expression was also inhibited by resveratrol. Thus, downregulation of the two anti-apoptotic proteins iNOS and Bcl-2 can contribute to the apoptotic effects of resveratrol in leukaemic B cells from chronic leukaemia. Our data suggest that this drug is of potential interest for the therapy of B-CLL.


PMID: 12060119 [PubMed - indexed for MEDLINE]